Research Article
Effectiveness and Safety of Zercepac and Reference Trastuzumab in the Neoadjuvant Setting for Early-Stage Breast Cancer: A Retrospective Cohort Study
| | | Total (N = 105) | Zercepac (n = 65) | Reference trastuzumab (n = 40) | |
| | Percentage of tumor shrinkage from baseline, % | 45.84 ± 19.15 | 47.58 ± 18.60 | 43.00 ± 19.92 | 0.235 |
| | Clinical response, n (%) | | | | 0.172 | | PR | 81 (77.1) | 53 (81.5) | 28 (70.0) | | | SD | 24 (22.9) | 12 (18.5) | 12 (30.0) | |
| | Pathological response, n (%) | | | | 0.933 | | Non-pCR | 31 (29.5) | 19 (29.2) | 12 (30.0) | | | pCR | 74 (70.5) | 46 (70.8) | 28 (70.0) | |
| | MP grade, n (%) | | | | >0.999 | | Grade 2 | 6 (5.7) | 4 (6.2) | 2 (5.0) | | | Grade 3 | 15 (14.3) | 9 (13.8) | 6 (15.0) | | | Grade 4 | 10 (9.5) | 6 (9.2) | 4 (10.0) | | | Grade 5 | 74 (70.5) | 46 (70.8) | 28 (70.0) | |
|
|
PR—partial response; SD—stable disease; pCR—complete pathological response.
|
